These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 1649718)

  • 21. [Iron-overload in patients on maintenance hemodialysis: diagnostic criteria, indications and treatment by desferrioxamine (author's transl)].
    Simon P; Bonn F; Guezennec M; Tanquerel T; Ksang
    Nephrologie; 1981; 2(4):165-70. PubMed ID: 7329501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low dose desferrioxamine can improve erythropoiesis in iron-overload hemodialysis patients without side effects.
    Lee CT; Liao SC; Hsu KT; Lam KK; Chen JB
    Ren Fail; 1999 Nov; 21(6):665-73. PubMed ID: 10586429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monitoring of iron requirements in renal patients on erythropoietin.
    Anastassiades EG; Howarth D; Howarth J; Shanks D; Waters HM; Hyde K; Geary CG; Yin JA; Gokal R
    Nephrol Dial Transplant; 1993; 8(9):846-53. PubMed ID: 8255518
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum soluble transferrin receptor reflects erythropoiesis but not iron availability in erythropoietin-treated chronic hemodialysis patients.
    Chiang WC; Tsai TJ; Chen YM; Lin SL; Hsieh BS
    Clin Nephrol; 2002 Nov; 58(5):363-9. PubMed ID: 12425487
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin.
    Wingard RL; Parker RA; Ismail N; Hakim RM
    Am J Kidney Dis; 1995 Mar; 25(3):433-9. PubMed ID: 7872321
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aluminium interference in the treatment of haemodialysis patients with recombinant human erythropoietin.
    Casati S; Castelnovo C; Campise M; Ponticelli C
    Nephrol Dial Transplant; 1990; 5(6):441-3. PubMed ID: 2122321
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEpo.
    Kosch M; Bahner U; Bettger H; Matzkies F; Teschner M; Schaefer RM
    Nephrol Dial Transplant; 2001 Jun; 16(6):1239-44. PubMed ID: 11390726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group.
    BMJ; 1990 Mar; 300(6724):573-8. PubMed ID: 2108751
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Iron overload in a beta thalassemia heterozygote of the intermediate type in a subject of Alsation origin. Results of iron chelation treatment].
    North ML; Lang JM; Bergerat JP; Giron C; Oberling F; Mayer S
    Nouv Rev Fr Hematol (1978); 1984; 26(5):317-21. PubMed ID: 6334273
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum transferrin receptor concentration is not indicative of erythropoietic activity in chronic hemodialysis patients with poor response to recombinant human erythropoietin.
    Hou CC; Wu SC; Wu SC; Yang WC; Huang TP; Ng YY
    Zhonghua Yi Xue Za Zhi (Taipei); 1998 Aug; 61(8):456-62. PubMed ID: 9745161
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Iron overload, but not treatment with desferrioxamine favours the development of septicemia in patients on maintenance hemodialysis.
    Seifert A; von Herrath D; Schaefer K
    Q J Med; 1987 Dec; 65(248):1015-24. PubMed ID: 3455553
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The management of iron metabolism in recombinant human erythropoietin treated dialysis patients by Dutch nephrologists.
    Kooistra MP; Marx JJ
    Nephrol Dial Transplant; 1997 May; 12(5):879-83. PubMed ID: 9175038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Experience with zinc protoporphyrin as a marker of endogenous iron availability in chronic haemodialysis patients.
    Baldus M; Salopek S; Möller M; Schliesser J; Klooker P; Reddig J; Gansert U; Brass H
    Nephrol Dial Transplant; 1996 Mar; 11(3):486-91. PubMed ID: 8710158
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation.
    Fishbane S; Frei GL; Maesaka J
    Am J Kidney Dis; 1995 Jul; 26(1):41-6. PubMed ID: 7611266
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Iron replacement in hemodialysis patients with a normal serum ferritin level].
    Riedel MK; Morgenstern T
    Dtsch Med Wochenschr; 2004 Sep; 129(36):1849-53. PubMed ID: 15368155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia.
    Tarng DC; Wei YH; Huang TP; Kuo BI; Yang WC
    Kidney Int; 1999 Jun; 55(6):2477-86. PubMed ID: 10354297
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of erythropoietin-resistant anaemia with desferrioxamine in patients on haemofiltration.
    Goch J; Birgegård G; Danielson BG; Wikström B
    Eur J Haematol; 1995 Aug; 55(2):73-7. PubMed ID: 7628592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Iron metabolism in thalassemia intermedia.
    Fiorelli G; Fargion S; Piperno A; Battafarano N; Cappellini MD
    Haematologica; 1990; 75 Suppl 5():89-95. PubMed ID: 2086386
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients.
    Schiesser D; Binet I; Tsinalis D; Dickenmann M; Keusch G; Schmidli M; Ambühl PM; Lüthi L; Wüthrich RP
    Nephrol Dial Transplant; 2006 Oct; 21(10):2841-5. PubMed ID: 16891647
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low levels of serum ferritin and moderate transferrin saturation lead to adequate hemoglobin levels in hemodialysis patients, retrospective observational study.
    Ogawa C; Tsuchiya K; Tomosugi N; Kanda F; Maeda K; Maeda T
    PLoS One; 2017; 12(6):e0179608. PubMed ID: 28662118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.